Cargando…
Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models
Bruton tyrosine kinase (BTK) is an important signaling hub that activates the B-cell receptor (BCR) signaling cascade. BCR activation can contribute to the growth and survival of B-cell lymphoma or leukemia. The inhibition of the BCR signaling pathway is critical for blocking downstream events and t...
Autores principales: | Lim, Ye Seul, Yoo, Sun-Mi, Patil, Vineet, Kim, Han Wool, Kim, Hyun-Hwi, Suh, Beomseon, Park, Ji Youn, Jeong, Na-rae, Park, Chi Hoon, Ryu, Je Ho, Lee, Byung-Hoon, Kim, Pilho, Lee, Song Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827040/ https://www.ncbi.nlm.nih.gov/pubmed/36269842 http://dx.doi.org/10.1182/bloodadvances.2022008121 |
Ejemplares similares
-
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022) -
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
por: Hamasy, A, et al.
Publicado: (2017) -
Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant
por: Libre, Camille, et al.
Publicado: (2020) -
ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020) -
Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
por: Yu, Xin, et al.
Publicado: (2022)